Navigation Links
Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
Date:9/25/2013

BASKING RIDGE, N.J., Sept. 25, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced it will present at the Aegis Capital Vegas Healthcare Conference, to be held September 25 – 28, 2013, at the Encore at Wynn Las Vegas.

David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Date: Friday, September 27, 2013 Time: 10:15 am (Pacific Time) Location:The Encore at Wynn Las Vegas; Las Vegas, NVABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.

For more information on Regado's Phase 3 REGULATE-PCI clinical study, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact:
Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664

Media - Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
2. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
4. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
5. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
6. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
7. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
8. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
11. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... Healthcare Edition 2017. The awards recognize medical centers that have implemented innovative products, ... efficiency of patient care protocols, competitive advantages, financial impact/value, and market need. The ...
(Date:8/21/2017)... ... August 21, 2017 , ... Boston Strategic ... experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide ... US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... Today Aether ... a project, funded by a Bill and Melinda Gates Foundation grant, to ... Bill & Melinda Gates Foundation, also known as the Gates Foundation, is said to ...
(Date:8/18/2017)... Jose, CA (PRWEB) , ... August 18, 2017 ... ... advanced precision Lithography Equipment for the Semiconductor, MEMS, and Microfluidics Industries, announces the ... features and specifications found more often in automated production mask aligners. OAI has ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):